Harmony Biosciences Inc. (HRMY)
Harmony Biosciences Statistics
Share Statistics
Harmony Biosciences has 57.35M shares outstanding. The number of shares has increased by 0.97% in one year.
| Shares Outstanding | 57.35M |
| Shares Change (YoY) | 0.97% |
| Shares Change (QoQ) | 0.55% |
| Owned by Institutions (%) | 92.67% |
| Shares Floating | 43.48M |
| Failed to Deliver (FTD) Shares | 30 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 5.53M, so 9.69% of the outstanding shares have been sold short.
| Short Interest | 5.53M |
| Short % of Shares Out | 9.69% |
| Short % of Float | 13.64% |
| Short Ratio (days to cover) | 9.84 |
Valuation Ratios
The PE ratio is 13.45 and the forward PE ratio is 8.89. Harmony Biosciences's PEG ratio is 0.75.
| PE Ratio | 13.45 |
| Forward PE | 8.89 |
| PS Ratio | 2.74 |
| Forward PS | 1 |
| PB Ratio | 2.97 |
| P/FCF Ratio | 8.95 |
| PEG Ratio | 0.75 |
Enterprise Valuation
Harmony Biosciences has an Enterprise Value (EV) of 1.52B.
| EV / Sales | 2.13 |
| EV / EBITDA | 6.51 |
| EV / EBIT | 6.92 |
| EV / FCF | 6.95 |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.31 |
| Quick Ratio | 3.27 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.07 |
| Interest Coverage | 10.91 |
Financial Efficiency
Return on Equity is 22.07% and Return on Invested Capital is 17.22%.
| Return on Equity | 22.07% |
| Return on Assets | 14.56% |
| Return on Invested Capital | 17.22% |
| Revenue Per Employee | $2.67M |
| Profits Per Employee | $542.88K |
| Employee Count | 268 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 21.79 |
Taxes
| Income Tax | 46.31M |
| Effective Tax Rate | 24.14% |
Stock Price Statistics
The stock price has increased by -0.86% in the last 52 weeks. The beta is 0.82, so Harmony Biosciences's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -0.86% |
| 50-Day Moving Average | 35.76 |
| 200-Day Moving Average | 34.8 |
| Relative Strength Index (RSI) | 39.56 |
| Average Volume (20 Days) | 657K |
Income Statement
In the last 12 months, Harmony Biosciences had revenue of 714.73M and earned 145.49M in profits. Earnings per share was 2.56.
| Revenue | 714.73M |
| Gross Profit | 557.92M |
| Operating Income | 190.83M |
| Net Income | 145.49M |
| EBITDA | 233.41M |
| EBIT | 209.3M |
| Earnings Per Share (EPS) | 2.56 |
Balance Sheet
The company has 453M in cash and 16.25M in debt, giving a net cash position of 436.75M.
| Cash & Cash Equivalents | 453M |
| Total Debt | 16.25M |
| Net Cash | 436.75M |
| Retained Earnings | 2.22M |
| Total Assets | 999.2M |
| Working Capital | 404.17M |
Cash Flow
In the last 12 months, operating cash flow was 219.82M and capital expenditures -1.15M, giving a free cash flow of 218.67M.
| Operating Cash Flow | 219.82M |
| Capital Expenditures | -1.15M |
| Free Cash Flow | 218.67M |
| FCF Per Share | 3.84 |
Margins
Gross margin is 78.06%, with operating and profit margins of 26.7% and 20.36%.
| Gross Margin | 78.06% |
| Operating Margin | 26.7% |
| Pretax Margin | 26.84% |
| Profit Margin | 20.36% |
| EBITDA Margin | 32.66% |
| EBIT Margin | 26.7% |
| FCF Margin | 30.59% |
Dividends & Yields
HRMY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 7.43% |
| FCF Yield | 11.17% |
Analyst Forecast
The average price target for HRMY is $55, which is 69.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $55 |
| Price Target Difference | 69.6% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
Scores
| Altman Z-Score | 5.15 |
| Piotroski F-Score | 8 |